Pharmacy Benefits Consulting
At Blue & Co., LLC we are uncommonly independent with a unique and customized approach to find clients the best solution based solely on their goals and objectives and not our sales or revenue goals.
Our team is comprised of pharmacists who have been exposed to all sides of the pharmacy supply chain and work to bring that unique perspective to our clients. Our independent approach allows us to work with all PBMs, both big and small, to find the best solution for the client and their employees.
Meet Our Pharmacy Benefits Expert
Chad Downing RPH,340B ACE, Senior Pharmacy Consultant
Chad Downing is a Senior Pharmacy Consultant with Blue & Co., specializing in pharmacy reimbursements and operations performance. Throughout his 20-year career as a healthcare and pharmacy executive, he has been recognized as a proven leader in operational and financial performance.
Chad earned his Bachelor of Science degree in pharmacy from Ohio Northern University. He obtained his EMBA from the Quantic School of Business and Technology. He maintains active pharmacy licenses in Illinois, Indiana, Kentucky and Ohio. Six Sigma Greenbelt certified. He holds an Apexus Advanced 340B Operations Certificate.
Blue & Co.’s Pharmacy Consulting Group uses a data-driven approach to provide a holistic picture of pharmacy spend in both pharmacy and medical venues. With a heavy focus on internal education during phase one of our contracts, we maximize your time with us by making sure we all have the same base level understanding from day one.
From day one, we provide client education to help you fully understand the pharmacy supply chain.
Our team will analyze your Pharmacy Benefit Manager contract terms and rates.
Our team of experts can work hand-in-hand with you and your PBM to ensure proper day-to-day performance and help with long term RFP support.
A comprehensive review for savings opportunities through variable copay, movement to lower cost/higher quality pharmacy channel, ensure proper payment terms based on contract definitions, and removal of non-essential drugs from plan formulary.
Related Articles View All Thought Leadership
Great news for 340B hospitals impacted by the reimbursement reductions initiated by the Center for Medicare and Medicaid Services (CMS) on January 1, 2018. Recently, CMS announced that the 2023 Medicare outpatient payment rates will be restored to rates prior to 2018 for affected hospitals. After many legal debates, court filings, and outcry from hospitals […]
In June, the Supreme Court gave hospitals participating in the 340B Drug Pricing Program a convincing victory ruling unanimously that the U.S. Center for Medicare & Medicaid Services (CMS) should not have reduced reimbursement for covered outpatient prescription drugs purchased by those hospitals. 340B Hospitals Challenge Payment Rates Hospitals challenged the 2018 and 2019 payment […]
Great news for 340B Hospitals affected by COVID-19. On March 15, 2022, President Biden signed into law the $1.5 trillion Consolidated Appropriations Acts, 2022. This bill allows Hospitals that have lost eligibility due to a decrease in their Medicare disproportionate share (DSH) percentage as a result of the COVID-19 public health emergency to regain access […]
Connect with our team.
To learn more about our services and areas of expertise, send us a message.